ArticleFrontiers in oncology2023

Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study.

Yongbiao Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.